OBJECTIVE: Increased levels of cell-free fetal DNA (f-DNA) in the maternal circulation are a potential noninvasive marker for fetal Down syndrome. Our objectives were to (1) determine whether f-DNA could be quantified by using archived serum and amniotic fluid, (2) examine whether serum f-DNA levels are elevated in Down syndrome pregnancies in a case-control series matched for gestational age and duration of sample storage, and (3) determine whether f-DNA levels are elevated in the amniotic fluid of Down syndrome fetuses. STUDY DESIGN: Eleven serum and six amniotic fluid samples previously collected and stored at -20°C from gravid women carrying a 47,XY,+21 fetus were each paired with five matched control samples of identical specimen type from gravid women carrying a presumed euploid male fetus. f-DNA concentration was quantified blindly by real-time polymerase chain reaction amplification for a Y-chromosome sequence. Matched rank-sum analysis and analysis of variance were used for analysis.
Trafficking of cellular and nuclear material between the maternal and fetal compartments has become increasingly recognized as a clinically important phenomenon. A recent advance in this field has been the discovery of significant quantities of circulating cell-free fetal DNA (f-DNA) within the maternal circulation that could potentially serve as a source of genetic material for noninvasive prenatal diagnosis of fetal chromosomal and genetic abnormalities.
Lo et al 1, 2 pioneered the demonstration and quantification of f-DNA in both maternal plasma and serum. Subsequent studies have determined that (1) free f-DNA can be detected in maternal blood as early as the seventh week of gestation, 2 (2) f-DNA concentrations generally increase as pregnancy progresses, with the most marked rise occurring in the late third trimester, 2 and (3) f-DNA is rapidly cleared from maternal plasma by undetermined mechanisms with an estimated half-life of 16 minutes. 3 The tissue origin of cell-free f-DNA in the maternal circulation is uncertain. The placenta appears to be the most likely candidate, but a recent study by Bianchi et al 4 has demonstrated that large amounts of cell-free f-DNA are also detectable within the amniotic fluid, identifying this as a possible reservoir of cell-free DNA from the fetus.
Apart from the characterization of f-DNA dynamics, other authors have examined the association between altered levels of f-DNA in the maternal circulation and complications of pregnancy including preeclampsia, 5 preterm labor, 6 hyperemesis gravidarum, 7 placenta accreta, 8 and fetal aneuploidy. [9] [10] [11] Much of this aneuploidy research has focused on fetal Down syndrome. Lo et al 9 and Zhong et al 10 have studied both fresh and archived midtrimester maternal plasma samples and reported 2-fold to 3-fold higher levels of f-DNA in Down syndrome pregnancies compared with euploid pregnancies. In contrast, a single study by Ohashi et al 11 was unable to confirm this finding with the use of maternal serum.
We conducted a blinded case-control study examining the concentrations of cell-free f-DNA in archived maternal serum and amniotic fluid from gravid women carrying male fetuses with Down syndrome compared with gravid women with presumed euploid male fetuses.
The purposes of this study were to (1) determine whether f-DNA could be extracted and quantified from archived serum and amniotic fluid samples, (2) examine whether serum f-DNA levels are elevated in Down syndrome pregnancies in a case-control series matched for gestational age (GA) and duration of sample storage, and (3) determine whether f-DNA levels are elevated in the amniotic fluid of fetuses with Down syndrome.
Methods
Archived serum specimens from 11 pregnant women confirmed to be carrying a singleton male fetus with Down syndrome (47,XY,+21) were obtained from the Division of Prenatal and Special Testing at Women and Infants' Hospital. Six of the 11 subjects with trisomy 21 fetuses also had stored amniotic fluid samples available. Male fetuses were required in this study because the use of DNA probes specific for the Y chromosome of a male fetus is currently the principal way to differentiate f-DNA from maternal DNA. Each case was paired with five controls of identical specimen type from gravid women carrying presumed euploid singleton male fetuses, matched for both GA and duration of specimen storage. These controls were systematically identified by using laboratory registration logs and included alternating samples received both before and after each case sample. Each set of matched samples (1 Down syndrome case and 5 controls) was coded by an investigator not involved in the DNA quantification. For several sets of matched samples, two specimens from gravid women carrying female fetuses were blindly included to serve as negative controls for the assay.
Blood samples were initially obtained for maternal serum screening between 15 and 19 weeks' gestation by standardized protocol. Amniotic fluid samples were obtained for indicated prenatal diagnostic testing between 16 and 18 weeks. All samples were collected between March 1999 and July 2000. Residual specimens were saved and stored at -20°C until analysis. Approval was obtained from the investigational review boards of the respective institutions.
Archived samples were thawed at 37°C and centrifuged at 13,500g for 10 minutes. Supernatant (400 µL) was used for DNA extraction. The concentrations of cell-free f-DNA in the samples were determined by real-time quantitative polymerase chain reaction (PCR) by using a Perkin-Elmer Applied Biosystems 7700 Sequence Detector (Foster City, Calif), by methods similar to those previously described by Bianchi et al. 4 Each sample was analyzed twice or in triplicate. The DYS1 locus of the Y chromosome was used to detect and quantify male DNA.
An amplification plot of cycle number and ∆Rn (fluorescent intensity over background) was generated from each reaction well (Fig 1, A) . Reference amplification curves were concurrently generated with the use of standardized male DNA samples. A standard curve of threshold cycle (cycle at which the amplification curve attains the threshold ∆Rn value) against reference DNA concentration was generated (Fig 1, B) . On the basis of this standard curve, the initial quantity of DNA in each unknown sample was calculated by methods previously described by Lo et al. 2 The results were expressed as genome-equivalents per milliliter (GE/mL) by using a conversion of 6.6 pg of DNA per cell. 5 Statistical analysis was performed using SAS/MIXED (SAS Institute, Cary, NC) and SPSS (SPSS, Chicago, Ill) software.
Results
Fig 2 illustrates the mean DNA concentrations from each of the serum samples, as a function of GA. The median values for the control samples were calculated by weighted log-linear regression analysis (upward sloping line) and suggest that f-DNA concentrations increase during this period of gestation. f-DNA levels from the Down syndrome group were uniformly above the control median for each week of gestation.
Quantitative DYS1 amplification data were first examined by using matched rank sum analysis. The ranks of the mean serum DNA concentrations from each of the trisomy 21 samples were found to be significantly higher than the expected rank of 3.5, with a mean observed rank of 5.0 (Fig 3, P ≤ .005, Z = 2.790, χ 2 = 8.45). Rank analysis of the amniotic fluid samples did not demonstrate a statistically significant group effect with a mean observed rank of 2.5 (P = .815).
To quantify the difference between cases and controls, these data were examined with a three-factor, mixed-model analysis of variance, adjusting for sample group, matched sample set, and sample run. The Table shows the adjusted means from the serum samples: 41.2 GE/mL (95% CI 31.6-50.7 GE/mL) for the trisomy 21 group and 24.2 GE/mL (95% CI 20.0-28.4 GE/mL) for the control group (P = .002). There was a 1.7-fold higher serum concentration of f-DNA in the Down syndrome group when compared with the euploid control group. Consistent with the results of the nonparametric analysis, the adjusted means from the amniotic fluid samples were not statistically different (P = .28).
We also examined the effect of the duration of sample storage on f-DNA concentration. We limited the analyses only to control samples from 16 weeks' gestation to account for the effect of GA. We appreciated an inverse correlation that approached statistical significance between the median concentrations of f-DNA in the serum control samples at 16 weeks' gestation and the duration of sample storage in months of -0.66 GE/mL per month of storage (Fig 4, R 2 = 0.095, P = .071). No effect due to storage was noted among the amniotic fluid control samples.
Comment
Our data indicate that the concentration of cell-free f-DNA in archived maternal serum is 1.7 times higher in pregnancies complicated by fetal Down syndrome compared with euploid pregnancies of the same GA and duration of storage. In this study, we have validated and extended prior reports by using a matched case-control series and demonstrated that archived serum can be a useful source of clinical material for retrospective analysis. In addition, we have suggested for the first time that there may be an effect from the duration of specimen storage on the concentration of f-DNA extracted from archived maternal serum. As a result, future studies that use archived samples may need to account for this effect, if subsequent studies confirm this trend.
Elevated levels of f-DNA were not observed in the archived amniotic fluid of fetuses with Down syndrome. Although no definitive conclusions can be made from this preliminary finding, the absence of a parallel relationship suggests that the f-DNA found in the maternal circulation may not originate in amniotic fluid.
Lo et al 9 were first to show higher levels of cell-free f-DNA in the plasma of women carrying Down syndrome fetuses. They analyzed fresh plasma samples from Hong Kong and demonstrated 3-fold higher median f-DNA concentrations in six Down syndrome pregnancies than in 18 GA-matched euploid pregnancies. Analysis of separate plasma samples from Boston showed median f-DNA concentrations two times higher in seven Down syndrome pregnancies compared with 19 GA-matched euploid pregnancies.
Zhong et al 10 confirmed this finding in a retrospective analysis of archived plasma by demonstrating a 2-fold elevation in the mean f-DNA level in 15 Down syndrome pregnancies compared with 29 euploid pregnancies but did not mention controlling for GA or the duration of sample storage.
One prior study investigated whether this relationship is seen in maternal serum. Ohashi et al 11 reported a comparison of f-DNA levels using SRY sequence probes that included 5 subjects with 47,XY,+21 fetuses and 55 subjects with 46,XY fetuses. They found no significant difference between the two groups (P = .698). GA was not controlled for in this study.
Our findings using serum samples differ from those previously described by Ohashi et al. One possible reason is differences in the control groups used by each study. The control group in in the study by Ohashi et al included 55 subjects of varying gestational ages between 15 and 17 weeks, for which the length of storage time was not specified. In contrast, our study was a case-control comparison, controlling for both GA and duration of storage of each sample.
We believed that it was necessary to account for these variables because (1) a prior study by Lo et al 2 had shown that f-DNA levels are GA dependent, gradually rising as pregnancy advances, and (2) it was unknown at the time whether the duration of freezer storage for these samples would affect the amount of extractable f-DNA. As it turns out, the data from our control samples suggest effects on f-DNA concentration from both GA and from extended specimen storage. Further research examining the effect of freezer storage on f-DNA concentration is needed to confirm this specific trend. Another difference between this study and the study by Ohashi et al is the choice of primer sequences. Ohashi et al amplified a sequence on the SRY locus, whereas we amplified a sequence on the DYS1 locus. Differences in the number of Y chromosome repeats between SRY and DYS1 could potentially influence the sensitivity of the assays for f-DNA. Although this should not theoretically affect the relative f-DNA concentrations within each study, the absolute concentrations may not be comparable.
We have identified several potential limitations of our study. First, our serum control group was composed of subjects with presumed euploid fetuses because karyotypes were not routinely performed on members of this group. Each neonatal delivery record was reviewed to confirm that no clinical stigmata of Down syndrome were noted after birth. Although this does not exclude the possibility of aneuploidy in the control group, it is unlikely to have significantly contributed to our results.
Second, as with all quantitative DNA assays, real-time PCR is subject to potential contamination. Because of this, sera from female pregnancies were included in a blinded fashion to serve as negative controls. Among 22 female controls included in the study, only one had evidence of presumed contaminating male DNA. Furthermore, all 102 male serum and amniotic fluid samples had demonstrable amplification. Thus, we are confident that the results of our study are representative of our samples, although contamination cannot be completely eliminated as a potential confounder.
The ability to quantify altered levels of cell-free f-DNA in the maternal midtrimester serum of trisomy 21 pregnancies naturally leads to questions regarding its clinical application as a screening marker for Down syndrome. Although these initial data are encouraging, certain issues remain to be addressed. At present, measurement of f-DNA can only be performed in pregnancies with male fetuses using Y-chromosome-specific sequences. The development of definitive methods for female f-DNA quantification is needed before widespread clinical use can be contemplated. A recent study introducing the use of paternally derived differential DNA methylation to detect female f-DNA in maternal plasma appears promising. 12 Furthermore, our data and that of previous authors suggest that there is considerable overlap of f-DNA levels between trisomy 21 and euploid fetuses. It is unlikely that f-DNA could stand alone as a noninvasive screening marker, but would more likely be used in combination with other serum analytes currently in clinical use. Continued investigation is necessary before f-DNA can be considered a potential screening marker for fetal aneuploidy.
Finally, the tissue origin of f-DNA in the maternal circulation has yet to be determined. It has been theorized that either placental abnormalities or increased cellular exchange between the maternal and fetal compartments may play a role in altering DNA levels. It is intriguing to note that in cases of Down syndrome, other markers of placental origin such as hCG and inhibin-A are also elevated. It is possible that the observed elevations of f-DNA levels in our case group reflect a similar biologic pathway. Further investigation is required to understand the physiology of maternal-fetal trafficking and how pathologic conditions such as Down syndrome affect this interaction between mother and fetus.
